Patents by Inventor Akira Niwa

Akira Niwa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR INDUCING DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO MESODERMAL CELLS
    Publication number: 20130011924
    Abstract: The present invention provides a method for inducing differentiation of pluripotent stem cells into mesodermal cells, comprising the step of culturing pluripotent stem cells in a serum-free medium without forming an embryoid body and without coculturing with cells from a different species.
    Type: Application
    Filed: March 18, 2011
    Publication date: January 10, 2013
    Applicant: KYOTO UNIVERSITY
    Inventors: Akira Niwa, Tatsutoshi Nakahata, Toshio Heike
  • Treating agent for irritable bowel syndrome
    Patent number: 7683090
    Abstract: Pharmaceutical compositions for treatment of irritable bowel syndrome including non-constipated irritable bowel syndrome such as diarrhea-predominant irritable bowel syndrome and alternating constipation/diarrhea irritable bowel syndrome in male and female patients, which may comprise administering a patient with from 0.001 to 0.05 mg of ramosetron hydrochloride as a daily dose or an equivalent molar amount of ramosetron or its pharmaceutically acceptable other salt.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: March 23, 2010
    Assignee: Astellas Pharma Inc.
    Inventors: Akito Nishida, Akira Niwa, Yutaka Atsuta
  • Treating agent for irritable bowel syndrome
    Patent number: 7358270
    Abstract: A therapeutic method and pharmaceutical compositions for treatment of irritable bowel syndrome including non-constipated irritable bowel syndrome such as diarrhea-predominant irritable bowel syndrome and alternating constipation/diarrhea irritable bowel syndrome in male and female patients, which may comprise administering a patient with from 0.001 to 0.05 mg of ramosetron hydrochloride as a daily dose or an equivalent molar amount of ramosetron or its pharmaceutically acceptable other salt.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: April 15, 2008
    Assignee: Astellas Pharma Inc.
    Inventors: Akito Nishida, Akira Niwa, Yutaka Atsuta
  • Treating agent for irritable bowel syndrome
    Publication number: 20070037866
    Abstract: A therapeutic method and pharmaceutical compositions for treatment of irritable bowel syndrome including non-constipated irritable bowel syndrome such as diarrhea-predominant irritable bowel syndrome and alternating constipation/diarrhea irritable bowel syndrome in male and female patients, which may comprise administering a patient with from 0.001 to 0.05 mg of ramosetron hydrochloride as a daily dose or an equivalent molar amount of ramosetron or its pharmaceutically acceptable other salt.
    Type: Application
    Filed: October 18, 2006
    Publication date: February 15, 2007
    Applicant: Astellas Pharma Inc.
    Inventors: Akito Nishida, Akira Niwa, Yutaka Atsuta
  • Treating agent for irritable bowel syndrome
    Publication number: 20050192329
    Abstract: A therapeutic method and pharmaceutical compositions for treatment of irritable bowel syndrome including non-constipated irritable bowel syndrome such as diarrhea-predominant irritable bowel syndrome and alternating constipation/diarrhea irritable bowel syndrome in male and female patients, which may comprise administering a patient with from 0.001 to 0.05 mg of ramosetron hydrochloride as a daily dose or an equivalent molar amount of ramosetron or its pharmaceutically acceptable other salt.
    Type: Application
    Filed: January 28, 2005
    Publication date: September 1, 2005
    Applicant: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Akito Nishida, Akira Niwa, Yutaka Atsuta
  • Naphthyridine derivatives and pharmaceutical compositions thereof
    Patent number: 5817670
    Abstract: 1,8-Naphthyridine derivatives represented by the following general formula (I), salts thereof, hydrates thereof and solvates thereof. ##STR1## They have an activity to inhibit type IV phosphodiesterase and are useful as agents for the prevention and treatment of respiratory diseases, inflammatory diseases accompanying organ transplantation, systemic or local arthropathy, proliferative diseases, micturition-related diseases and diseases in which tumor necrosis factor (TNF) and other cytokine (IL-1, IL-6 or the like) are concerned.
    Type: Grant
    Filed: January 30, 1997
    Date of Patent: October 6, 1998
    Assignee: Yamanouchi Pharmaceutical Co., Ltd.
    Inventors: Kazuhisa Takayama, Masahiro Iwata, Yoshinori Okamoto, Motonori Aoki, Akira Niwa, Yasuo Isomura